Risk factors and prognosis of sentinel lymph node metastasis in breast-conserving breast cancer: A retrospective study based on the SEER database

Ruihao Liu,Jian Chen,Wei Cao,Ting Li,Yulong Liao,Yingliang Li
DOI: https://doi.org/10.1097/md.0000000000037263
IF: 1.6
2024-03-13
Medicine
Abstract:Sentinel lymph node (SLN) was found during dorsal phallic lymphangiography by Cabanas in 1977, [ 1 ] and was the first lymph node stop for primary tumor metastasis. When SLN did not have metastasis, there was a very low probability of non-sentinel lymph node metastasis (SLNM). [ 2 ] sentinel lymph node biopsy (SLNB) provides prognostic information and guides adjuvant treatment. NSABP-B32 study confirmed that negative axillary sentinel lymph node biopsy exempted axillary lymph node dissection. [ 3 ] Multiple prospective clinical studies [ 4–6 ] (such as ACOSOG Z0011, AMAROS, IBCSG 23-01, etc.) have shown that For breast cancer patients with sentinel lymph node metastasis (1–2 SLNM, early breast cancer with cN0 SLN positive, sentinel lymph node micro-metastases), whether or not ALND has no significant effect on postoperative recurrence and survival. Now SLNB is recommended for clinically negative axillary patients after neoadjuvant chemotherapy. [ 7 ] At present, breast-conserving surgery and SLNB have been widely recognized as radical surgical methods for patients.
medicine, general & internal
What problem does this paper attempt to address?